Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever

Rafael Holdings' Phase 3 clinical trial of a drug named Trappsol Cyclo just got over. Results of the trial are expected in the second half of 2026. RFL has a runway of 4 to 5 quarters. RFL could end up borrowing money in the event of trial results getting delayed or FDA approval getting stretched. In my opinion, RFL does present a compelling investment case for risk-appetite investors. Conservative investors should wait until the trial results are out.

Seeking Alpha • Jun 29, 2026

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

NEWARK, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter fiscal year 2026 ended April 30, 2026.

GlobeNewsWire • Jun 11, 2026

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Topline results are expected to be announced in second half of calendar 2026 The company has had a pre-NDA meeting with the FDA and expects to submit an NDA in second half of calendar 2026 The company has received acknowledgement from the FDA that our US Expanded Access Program (EAP) can proceed NEWARK, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced the last patient has completed the final 96-week study visit in the pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C (NPC).

GlobeNewsWire • Jun 10, 2026

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”

License of the MIT patent strengthens Rafael's intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer's Disease License of the MIT patent strengthens Rafael's intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer's Disease

GlobeNewsWire • Apr 22, 2026

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

NEWARK, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the second quarter fiscal year 2026 ended January 31, 2026.

GlobeNewsWire • Mar 16, 2026

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

NEWARK, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter fiscal year 2026 ended October 31, 2025.

GlobeNewsWire • Dec 11, 2025

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for  Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation of the Data Monitoring Committee (DMC) following their review of prespecified safety and efficacy date at 48 weeks

GlobeNewsWire • Oct 29, 2025

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

NEWARK, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) sadly announced today the passing of its Lead Independent Director, Stephen Greenberg, and the appointment of Alan Grayson to its Board of Directors. Mr. Grayson will serve on the Compensation, Corporate Governance and Nominating Committees. Separately, the Company also announced that Markus Sieger, an existing Board member, will join the Audit Committee as its Chair and has been elected as Lead Independent Director.

GlobeNewsWire • Oct 28, 2025

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

First data on treatment of NPC1 with Trappsol ® Cyclo™ (hydroxypropyl-beta-cyclodextrin) in this age group over a period of 48 weeks At 48 weeks of the sub-study, 7 of 9 patients 1 showed stabilization or improvement in CGI-S score Data presented at the15 th International Congress of Inborn Errors of Metabolism (ICIEM) NEWARK, N.J., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today that data from Cyclo Therapeutics' Phase 3 TransportNPC™ open-label, single-arm sub-study evaluating Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) for Niemann-Pick Disease Type C1 (“NPC1”) were presented at the 15th International Congress of Inborn Errors of Metabolism (ICIEM).

GlobeNewsWire • Sep 16, 2025

Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

NEWARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today that its subsidiary Cyclo Therapeutics has had two abstracts selected for presentation from its programs evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 at the upcoming 15 th International Congress of Inborn Errors of Metabolism (ICIEM) being held September 2-6, 2025 in Kyoto, Japan.

GlobeNewsWire • Aug 27, 2025